Olanzapine for the Prevention and Treatment of ICU Delirium: Protocol for a Systematic Review With Meta‐Analysis
Acta Anaesthesiologica Scandinavica · 2026
DOI: 10.1111/aas.70352 ↗At a glance
Systematische Übersicht in Acta Anaesthesiologica Scandinavica, 2026. Written by Benedikte Liebetrau and 5 co-authors. Institution: Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark. Major MEDLINE topics: Delirium, Olanzapine, Intensive Care Units, Antipsychotic Agents. 57 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk Fonden, Hjerteforeningen, Central Denmark Region Health Research Foundation.
Topics: Delir
Abstract (original language)
Background
Intensive care unit (ICU) delirium is a multifactorial acute brain dysfunction associated with prolonged hospitalization, increased morbidity and mortality, and higher healthcare costs. Despite these substantial negative impacts of delirium, the optimal prevention and treatment strategies are unclear. Olanzapine, an atypical antipsychotic drug, is commonly used for delirium management. We will perform an updated systematic review and meta‐analysis to assess the benefits and harms of olanzapine for the prevention and treatment of ICU delirium.
Methods
This protocol is developed in accordance with the recommendations of The Cochrane Collaboration and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis Protocols (PRISMA‐P) guidelines. We will include all randomized clinical trials (RCTs) evaluating prophylactic or therapeutic olanzapine versus any comparator, including pharmacological, non‐pharmacological, placebo, or routine care/no specific delirium‐directed intervention (treated as a single comparator) in ICU patients. Observational studies will be included solely to address potential harms. We will systematically search the following databases: Embase, MEDLINE, The Cochrane Library, Web of Science, CINAHL, Scopus, and PsycINFO, as well as clinical trial registries. We will perform meta‐analysis and trial sequential analysis (TSA) to investigate the risk of both Type I and II errors. We will assess the risk of bias using the Cochrane Risk of Bias tool (RoB‐2). The quality of trials will be evaluated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The review is registered in the PROSPERO database (CRD420261474813). Outcomes The primary outcome is days alive and out of the hospital. The secondary outcomes include all‐cause mortality at 90 days, number of CAM‐ICU (Confusion Assessment Method for the Intensive Care Unit) negative days at 30 days, number of days without pharmacological treatment for delirium other than study drug during the intervention period and serious intervention‐related harms.
Discussion
This protocol outlines the methodology we will use in a systematic review with meta‐analysis designed to evaluate the beneficial and harmful effects of olanzapine for prevention and treatment of delirium in ICU patients. The findings of the systematic review will be disseminated through peer‐reviewed publication. We hope this review will inform future RCTs and improve clinical practice.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Anesthesiology and Intensive Care, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Department of Cardiology, the Heart Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Department of Cardiothoracic Anesthesiology and Intensive Care, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Neuroanesthesiology, The Neuroscience Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
ORCID profiles: Benedikte Liebetrau, Andreas Ruhvald Madsen, Sören Möller, Markus Harboe Olsen, Sebastian Wiberg, Simon Mølstrøm
Funding
- Novo Nordisk Fonden
- Hjerteforeningen
- Central Denmark Region Health Research Foundation
Cite
APA
Liebetrau, B., Madsen, A. R., Möller, S., Olsen, M. H., Wiberg, S., & Mølstrøm, S. (2026). Olanzapine for the Prevention and Treatment of ICU Delirium: Protocol for a Systematic Review With Meta‐Analysis. Acta Anaesthesiologica Scandinavica. https://doi.org/10.1111/aas.70352
Vancouver
Liebetrau B, Madsen AR, Möller S, Olsen MH, Wiberg S, Mølstrøm S. Olanzapine for the Prevention and Treatment of ICU Delirium: Protocol for a Systematic Review With Meta‐Analysis. Acta Anaesthesiologica Scandinavica. 2026. doi:10.1111/aas.70352
BibTeX
@article{Liebetrau2026,
author = {Liebetrau, Benedikte and Madsen, Andreas Ruhvald and Möller, Sören and Olsen, Markus Harboe and Wiberg, Sebastian and Mølstrøm, Simon},
title = {Olanzapine for the Prevention and Treatment of ICU Delirium: Protocol for a Systematic Review With Meta‐Analysis},
journal = {Acta Anaesthesiologica Scandinavica},
year = {2026},
doi = {10.1111/aas.70352}
}
EUVIMED